See what CeloNova is doing about COVID-19 Read More

CeloNova BioSciences, Inc.

Pioneers in Cardiovascular Innovation

Our Company

CeloNova BioSciences, Inc. is an innovative global medical device leader transforming the treatment of cardiovascular disease and addressing the treatment gap in patients at high risk of bleeding.

CeloNova BioSciences develops, manufactures and markets a family of products based upon its novel Polyzene-F nanocoating technology. This next-generation nanocoating is the result of years of rigorous scientific research and German-engineering and has been widely published in numerous academic articles to date.

In 2015, CeloNova BioSciences interventional radiology product lines were acquired by Boston Scientific. Read more here. Moving forward, CeloNova BioSciences is looking to develop new PzF applications for implantable medical devices that will help patients and change the practice of medicine around the world.

Celonova BioSciences Inc.

Shaping the Future of Quality & Safety

In January 2018, CeloNova became one of a handful of companies in the U.S. selected to support advancements in medical device quality and safety through partnership with the FDA’s Case for Quality Voluntary Improvement Program (CFQ VIP).

This program identifies device manufacturers that consistently produce high-quality devices to help better focus FDA resources and promote best practices to help other manufacturers raise their level of quality and safety. Through the program’s partnership, CeloNova aims to further advance quality of care in patients in the U.S. 1


CeloNova Named Top 10 Cardiovascular Device Companies of 2019 by MedTech Outlook

In April of 2019, MedTech Outlook recognizes CeloNova BioSciences, Inc. as a pioneer at the forefront of cardiovascular innovation by naming the company as one of the top 10 cardiovascular companies of 2019.

CeloNova’s foundation of innovation has led to the successful manufacturing and marketing of a family of products, including the COBRA PzF NanoCoated Coronary Stent (NCS), based upon its proprietary Polyzene-F (PzF) 60nanocoating technology, a revolutionary surface coating designed to optimize implant interaction within the body. Through its commitment to PzF innovation, CeloNova is transforming clinical practice and promoting positive outcomes in patients around the world.

Top 10 CardioVascular Device Companies - 2019 Logo - Jpeg

Board Members

Mark C. Bates, MD, DSC, FACC, FSCAI

Chairman of the Board

Dr. Bates is Director of the CAMC Cardiovascular Medicine Fellowship and Senior Scientist for Cardiovascular Research at the CAMC Research Institute. He is the Founder and Co-Director of the CAMC Vascular Center of Excellence and is Clinical Professor of Medicine and Surgery at West Virginia University School of Medicine in Charleston, WV. He is considered a thought leader in cardiovascular medicine having authored over 100 manuscripts/book chapters. Dr. Bates has performed 1000s of cardiovascular procedures and has been the site principle investigator (PI) and national PI for several US and International Clinical Trials. Dr. Bates is also a successful entrepreneur and inventor. His passion in the field of endovascular surgery has resulted in key innovative advances with over 50 US issued / pending patents in the arenas of embolic protection, nanotechnology, stent design, cell therapy, catheter design, guide-wire design, drug eluting balloons and local drug delivery. He has been on the advisory boards of Guidant, Boston Scientific and Medtronic and has served on the Johnson & Johnson Opinion Leaders Council. He is also currently Chairman of the Board for Nexeon MedSystems, Nevada Corp. Mark graduated from West Virginia University School of Medicine and completed his Internal Medicine residency at WVU followed by a cardiovascular fellowship at the University of Kentucky. He then was retained as a Clinical Scholar in Interventional Cardiology and Research at UK followed by a Fellowship in Vascular Medicine and Complex Vascular Intervention / Research at the Dorros-Feuer CV Research Foundation / University of Wisconsin. In 2014 Dr. Bates was honored with a Doctor of Science Degree from University of Charleston and Received the American Heart Association Heart of Gold Award in 2015.

Thomas (Tim) Lyles, JD


Mr. Lyles is President of Mission City Management, Inc. and MedCare Investment Funds. Mr. Lyles has managed an investment portfolio for over twenty years, including both public and large private companies. He also serves on numerous for-profit and non-profit Boards of Directors. Mr. Lyles’ primary responsibility is President of a private holding company, which oversees both strategic and operational issues for various fund portfolios. Mr. Lyles has helped organize each fund in the MedCare Investment Funds group and has served as President of each fund since 1991. As a founding partner, Mr. Lyles was an active member of management in founding Renal Care Group along with Dr. Jacobson and the late Sam Brooks. Mr. Lyles, through his role as President of MedCare Investment Funds, has founded and established numerous health care companies. From 1984 to 1989, Mr. Lyles was an Attorney with the law firm of Haynes and Boone in Dallas, Texas. During 1986 and 1987, he taught Real Estate Financing at Southern Methodist University in Dallas. From 1983 to 1984, he was appointed a Briefing Attorney for the Chief Justice of the Supreme Court of Texas. Tim received his Juris Doctorate Cum Laude from SMU School of Law. Prior to attending law school, he was employed by KPMG Peat Marwick. Mr. Lyles earned an accounting degree from Texas A & M University, where he graduated Summa Cum Laude. In addition, Mr. Lyles is a Certified Public Accountant and has written material for the Texas State Bar and has been a speaker for the State Bar of Texas and the Dallas Bar.

Harry Jacobson, MD


Dr. Jacobson is former Vice Chancellor for Health Affairs at Vanderbilt University and Chief Executive Officer of Vanderbilt University Medical Center (VUMC). During his more than 11 years of tenure, VUMC revenues grew from $750 million to $2.5 billion, while delivering superior care at substantially lower costs than those in similar hospitals. Its federally-funded NIH research program moved from 24th to the top 10 in the country, and over $1 billion of newly-constructed research and patient care facilities were opened during his tenure. Dr. Jacobson has been a successful investor and entrepreneur, as well, having founded or co-founded more than ten companies, including Contact Software, Renal Care Group and Ambulatory Services of America. He has been both a formal and informal advisor to several venture and private equity funds. He formerly served on the Board of Directors of Kinetic Concepts, Inc. and Merck. Dr. Jacobson currently serves as Chairman of the Board of MedCare Investment Funds, a privately-held healthcare investment group. Harry received his Doctor of Medicine degree from the University of Illinois in 1972 and completed his medical residency at Johns Hopkins Hospital and specialty training in nephrology at the University of Texas Health Science Center in Dallas.

Goetz M. Richter, MD, PHD


Dr. Richter is the Director of the Clinics for Diagnostic and Interventional Radiology of the Klinikum Stuttgart. Dr. Richter is a co-founder of IMED, which became CeloNova BioSciences, Inc. in October of 2005. He is widely recognized as one of the pioneers in the development of stent technology, and was one of the first physicians to place a stent in a human being. He was one of the Principal Investigators and played a key role in the development and the clinical trials of the Palmaz Stent. A noted author and lecturer, Dr. Richter is regarded as one of the leading interventional radiologists in the world. Goetz completed his undergraduate work at the University of Stuttgart-Hohenheim and earned a Doctor of Medicine degree from University Freiberg. He is currently serving as the President of the German Society of Interventional Radiology.

Martin “Marty” Landon


Martin “Marty” Landon was named Chief Executive Officer of BioBridge Global in October 2016. He previously served as the President and Chief Executive Officer of CeloNova BioSciences, Inc. from 2014-2016, where he oversaw the sale of CeloNova’s interventional radiology business to Boston Scientific. Mr. Landon has over 25 years of experience in the healthcare industry. Mr. Landon has held senior positions varying from Corporate Controller to Chief Financial Officer and Chief Executive Officer of both public and private companies and is known and recognized for building and leading high-performance teams and value creating initiatives. From 1994 to 2012, Mr. Landon was employed by Kinetic Concepts, Inc. (KCI), a global medical device company, where he led numerous acquisitions, financial and securities transactions and developed and executed several major process improvement and I.T. initiatives that contributed to extraordinary geographic, revenue and earnings growth for the company, culminating in a $6.3B leveraged buyout by a consortium led by APAX Partners. Marty was a licensed Certified Public Accountant from 1984 to 2010 and received his Bachelor of Arts in Accounting from Benedictine College (KS). Mr. Landon is also a member of the Advisory Council of SAMMinistries in San Antonio, TX.

Bruce Tamargo


Mr. Tamargo has over 30 years of experience in the medical device industry. The majority of his career has been spent in the endovascular and cardiovascular commercial space, holding various leadership and senior leadership positions. His interventional cardiology business career began with ACS (Advanced Cardiovascular Systems, Inc., Santa Clara, CA), continuing on with the formation of Guidant Corporation (Indianapolis, IN). He worked through the integration of Guidant and Abbott Vascular (Abbott Laboratories, Chicago, IL). He retired recently as Divisional Vice President of Sales, Abbott Vascular. Since retiring, Mr. Tamargo has done consulting work including management skills development and mentoring. He currently serves on The Family Physician’s Patient Advisory Board in Canton, OH, exploring patient satisfaction metrics and best practices. Bruce Received a B.A. in Biology with English Literature and Theology minors from Malone University and completed additional coursework at Kent State University.

Gregory Oberholtzer


Gregory Oberholtzer, Senior Managing Director, WP Global Partners, has over 32 years of broad investment advisory experience with a focus on alternative asset management and financial product structuring for institutional clients.

Prior to joining WP Global, he was a Director of WestAM, where he was responsible for their small and middle market buyouts, special situations, and co-investments, and was a member of the Private Equity Executive Committee and Investment Committee. Prior to WestAM, Mr. Oberholtzer previously served as the Managing Director and Portfolio Manager of Forstmann-Leff International’s (FLI) Global Derivatives Group and was a Senior Vice President of Products and Strategies. Prior to FLI, Mr. Oberholtzer was a Director of Jefferies Analytical Trading Group at Jefferies Group, where he was involved in product structure and fund management in equities and listed derivatives. Mr. Oberholtzer has served as the president of two private financial services companies and was active in a successful family business for several years.

He is a board member or observer of Australis, BrightFarms, Illumitex, Monogram Foods, and VoloAgri, among other portfolio companies, and serves as an advisory board member of more than two dozen invested funds. He holds a B.B.A. from George Washington University.

Nurture Your Unique Potential

At CeloNova BioSciences, you’ll have the opportunity to further your potential by joining a team of cutting edge cardiovascular innovators and leaders dedicated to transforming the treatment of coronary artery disease. Here you’ll discover challenges that develop you professionally, allowing you to explore a customer-centric culture with a hunger for innovation and improvement.

For a complete list of available career opportunities please contact CeloNova Human Resources.

Email CeloNova